Go to deals
Healthcare

Protalix BioTherapeutics, Inc. has completed a private stock placement

Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.

Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Ruben  Eblagon

Ruben Eblagon

Principal

Tel Aviv, Israel
Oaklins Rosario
 Boaz  Levi

Boaz Levi

Partner

Tel Aviv, Israel
Oaklins Rosario
 Olga  Geyber

Olga Geyber

Support

Tel Aviv, Israel
Oaklins Rosario

Related deals

GeneTech Inc. has been acquired by Eurofins
Healthcare

GeneTech Inc. has been acquired by Eurofins

Noritsu Koki Co., Ltd. has sold GeneTech Inc. to Eurofins Clinical Testing Holding Lux S.à r.l.

Learn more
Dental Holding has been acquired by Advantage Partners
Healthcare

Dental Holding has been acquired by Advantage Partners

Noritsu Koki Co., Ltd. has sold Dental Holding Inc. to Advantage Partners Inc.

Learn more
MediCa group has been acquired by Repharm
Healthcare

MediCa group has been acquired by Repharm

CGP Management has sold MediCa group, the largest private provider of healthcare services in Lithuania, to Repharm.

Learn more